232 related articles for article (PubMed ID: 16176204)
1. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency.
Juhl CB; Pørksen N; Hollingdal M; Sturis J; Pincus S; Veldhuis JD; Dejgaard A; Schmitz O
Diabetes Care; 2000 May; 23(5):675-81. PubMed ID: 10834429
[TBL] [Abstract][Full Text] [Related]
3. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
[TBL] [Abstract][Full Text] [Related]
4. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
Owens DR; Luzio SD; Ismail I; Bayer T
Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
Rudovich NN; Leyck Dieken MG; Rochlitz H; Pfeiffer AF
Exp Clin Endocrinol Diabetes; 2004 Jul; 112(7):395-400. PubMed ID: 15239026
[TBL] [Abstract][Full Text] [Related]
6. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
Rosak C; Hofmann U; Paulwitz O
Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
8. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
Cozma LS; Luzio SD; Dunseath GJ; Langendorg KW; Pieber T; Owens DR
Diabetes Care; 2002 Aug; 25(8):1271-6. PubMed ID: 12145220
[TBL] [Abstract][Full Text] [Related]
10. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
[TBL] [Abstract][Full Text] [Related]
11. Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.
Cozma LS; Luzio SD; Dunseath GJ; Underwood PM; Owens DR
Diabetes Care; 2005 May; 28(5):1001-7. PubMed ID: 15855557
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
Van Gaal LF; Van Acker KL; De Leeuw IH
Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
[TBL] [Abstract][Full Text] [Related]
16. The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.
Østergård T; Degn KB; Gall MA; Carr RD; Veldhuis JD; Thomsen MK; Rizza RA; Schmitz O
J Clin Endocrinol Metab; 2004 Jan; 89(1):297-302. PubMed ID: 14715864
[TBL] [Abstract][Full Text] [Related]
17. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans.
Hollingdal M; Juhl CB; Dall R; Sturis J; Veldhuis JD; Schmitz O; Pørksen N
Diabetologia; 2002 Jan; 45(1):49-55. PubMed ID: 11845223
[TBL] [Abstract][Full Text] [Related]
19. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
20. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG
Diabetes Care; 1998 Nov; 21(11):1897-903. PubMed ID: 9802740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
